Home » Stocks » ZIOPHARM Oncology

ZIOPHARM Oncology Inc. (ZIOP)

Stock Price: $3.03 USD -0.02 (-0.49%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $3.04 +0.02 (0.50%) Aug 13, 7:55 PM

Stock Price Chart

Key Info

Market Cap 647.81M
Revenue (ttm) n/a
Net Income (ttm) -126.63M
Shares Out 214.15M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $3.03
Previous Close $3.04
Change ($) -0.02
Change (%) -0.49%
Day's Open 3.07
Day's Range 2.90 - 3.16
Day's Volume 3,537,269
52-Week Range 1.80 - 5.70

More Stats

Market Cap 647.81M
Enterprise Value 495.31M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 214.15M
Float 191.19M
EPS (basic) -0.69
EPS (diluted) -0.66
FCF / Share -0.24
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 32.13M
Short Ratio 21.63
Short % of Float 15.23%
Beta 2.46
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.94
Revenue n/a
Operating Income -66.75M
Net Income -126.63M
Free Cash Flow -50.65M
Net Cash 152.50M
Net Cash / Share 0.71
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -32.74%
ROE -112.36%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 5
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.93*
(96.03% upside)
Low
3.00
Current: $3.03
High
7.50
Target: 5.93
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue-0.156.396.864.331.370.800.800.67-
Revenue Growth--97.71%-6.88%58.38%215.51%71.63%0%19.94%--
Gross Profit-0.156.396.864.331.370.800.800.67-
Operating Income-57.86-53.91-53.49-165-120-43.50-57.71-102-71.40-24.55
Net Income-118154-54.32-165-120-31.78-57.11-96.13-63.78-32.67
Shares Outstanding16814413713012510185.9478.5566.0046.00
Earnings Per Share-0.700.96-0.53-1.32-0.96-0.31-0.66-1.22-0.97-0.71
Operating Cash Flow-40.85-49.46-54.67-58.33-0.01-36.65-59.51-78.83-38.84-19.69
Capital Expenditures-0.28-0.46-0.74-0.55-0.41-0.19-0.13-1.56-1.16-0.19
Free Cash Flow-41.14-49.92-55.41-58.88-0.42-36.84-59.64-80.39-39.99-19.88
Cash & Equivalents79.8761.8671.0781.1814142.9368.3373.4410560.48
Total Debt1.58---------
Net Cash / Debt78.2961.8671.0781.1814142.9368.3373.4410560.48
Assets10995.0510610615445.2471.7583.4010861.52
Liabilities14.109.4958.4258.3366.3511.4022.3734.9636.5030.97
Book Value95.0185.56-96.81-77.3087.3733.8449.3848.4571.6130.55
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ZIOPHARM Oncology Inc.
Country United States
Employees 73
CEO Laurence James Neil Cooper

Stock Information

Ticker Symbol ZIOP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZIOP

Description

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.